Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Nov 27, 2025; 17(11): 112679
Published online Nov 27, 2025. doi: 10.4254/wjh.v17.i11.112679
Published online Nov 27, 2025. doi: 10.4254/wjh.v17.i11.112679
Tumor necrosis factor alpha-induced protein 3: Biomarker discovery and therapeutic advancement in primary biliary cholangitis
Khaled Mohamed Mohamed Koriem, Department of Medical Physiology, Medical Research and Clinical Studies Institute, National Research Centre, Giza 12622, Egypt
Author contributions: Koriem KMM designed the overall concept and outline of the manuscript, contributed to the design of the manuscript, the writing and editing of the manuscript, and review of the literature.
Conflict-of-interest statement: The author declares that he has no conflict of interest to disclose.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Khaled Mohamed Mohamed Koriem, Professor, Department of Medical Physiology, Medical Research and Clinical Studies Institute, National Research Centre, 33 El-Buhouth Street, Dokki, P.O. Box, Giza 12622, Egypt. kkoriem@yahoo.com
Received: August 4, 2025
Revised: August 18, 2025
Accepted: September 28, 2025
Published online: November 27, 2025
Processing time: 116 Days and 22.8 Hours
Revised: August 18, 2025
Accepted: September 28, 2025
Published online: November 27, 2025
Processing time: 116 Days and 22.8 Hours
Core Tip
Core Tip: The novel work by Zang et al examined tumor necrosis factor alpha-induced protein 3 (TNFAIP3), a new biomarker, to predict ursodeoxycholic acid (UDCA) efficiency in primary biliary cholangitis (PBC). PBC patients' TNFAIP3 expression was significantly higher than that in healthy controls. The response to UDCA in PBC was substantially impacted by both TNFAIP3 and fatigue. TNFAIP3 may be a suitable biomarker or therapeutic target for PBC because its expression was also connected with splenomegaly, alkaline phosphatase, albumin, total bilirubin, and age.